Winchester AK, Peterson RA, Carter E, Sammel MD. Impact of COVID-19 Social Distancing Policies on Traffic Congestion, Mobility, and NO2 Pollution. Sustainability. 2021; 13(13):7275. https://doi.org/10.3390/su13137275
Jennifer K. Richer, Nicole S. Spoelstra, Alyse Winchester, Julia Wulfkuhle, Sharon B. Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony D. Elias. Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2867.
Anthony D Elias, Monica Fournier, Gregory A Vidal, Sharon Sams, Nicole Spoelsta, Peter Kabos, Jennifer R Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Julia Wulfkuhle, Emanuel Petricoin, Lisa Carter, Kathryn Zolman, Stephanie Armstead, Alyse Winchester, Tessa McSpadden, Gloria Crawford, Virginia Borges, Dexiang Gao, Jennifer Richer. Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS12-06.
Anthony D Elias, Nicole Spoelsta, Gregory A Vidal, Sharon Sams, Peter Kabos, Jennifer R Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Lisa Carter, Kathryn Zolman, Stephanie Armstead, Alyse Winchester, Virginia Borges, Julia Wulfkuhle, Emanuel Petricoin, Dexiang Gao, Jennifer Richer. Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS12-14.
Richer J, Spoelstra N, Winchester A, Wulfkuhle J, Sams S, Vidal G, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges V, Gao D, Petricoin E, Elias A. Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide. Tumor Biology. Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA; ; American Association for Cancer Research; c2021. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2021-2867 DOI: 10.1158/1538-7445.AM2021-2867
Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g) CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):10531-10531. Available from: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.10531 DOI: 10.1200/JCO.2021.39.15_suppl.10531
Elias A, Fournier M, Vidal G, Sams S, Spoelsta N, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, Wulfkuhle J, Petricoin E, Carter L, Zolman K, Armstead S, Winchester A, McSpadden T, Crawford G, Borges V, Gao D, Richer J. Abstract PS12-06: Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC). Poster Session Abstracts. Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas; ; American Association for Cancer Research; c2021. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS20-PS12-06 DOI: 10.1158/1538-7445.SABCS20-PS12-06
Anosheh Afghahi, Sydney Marsh, Alyse Winchester, Dexiang Gao, Hannah Parris, Lisen Axell, Leif W. Ellisen, Erin Wysong Hofstatter, Allison W. Kurian, Marie Wood, Dana Zakalik, Carol-Ann Mullin, Jennifer Lee Caswell-Jin, Virginia F. Borges, Nadine M. Tung. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study [abstract]. Journal of Clinical Oncology 2021 39:15_suppl, 10531-10531
Elias A, Spoelsta N, Vidal G, Sams S, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Carter L, Zolman K, Armstead S, Winchester A, Borges V, Wulfkuhle J, Petricoin E, Gao D, Richer J. Abstract PS12-14: Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer. Poster Session Abstracts. Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas; ; American Association for Cancer Research; c2021. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS20-PS12-14 DOI: 10.1158/1538-7445.SABCS20-PS12-14
Winchester A, Peterson R, Carter E, Sammel M. Impact of COVID-19 Social Distancing Policies on Traffic Congestion, Mobility, and NO2 Pollution. Sustainability. 2021 June 29; 13(13):7275-. Available from: https://www.mdpi.com/2071-1050/13/13/7275 DOI: 10.3390/su13137275
Habenicht LM, Staley AW, Clancy BM, Bozan S, Manuel CA, Fong DL, Nicklawsky AG, Klug A, Leszczynski JK. Characterization of a Jumping Stereotypy in Gerbils (Meriones unguiculatus) and Assessment of Opaque Tubing Enrichment on Stereotypies and Breeding. J Am Assoc Lab Anim Sci. 2022 Mar 1;61(2):149-158. doi: 10.30802/AALAS-JAALAS-21-000101. Epub 2022 Feb 9. PubMed PMID: 35140007; PubMed Central PMCID: PMC8956210.
Jennifer K. Richer, Nicole S. Spoelstra, Alyse Winchester, Julia Wulfkuhle, Sharon B. Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony D. Elias. Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2867.
Denise Smith (Poster): Smith, D.C., Barton, A.J., Hernandez, T.L., Thumm, E.B., Willems, E.L., Staley, A.W., & Sheeder, J.L. (2022, May 22-26). Health system factors and racial and ethnic disparities in cesarean birth utilization among low-risk women. [Poster presentation]. American College of Nurse-Midwives, Chicago, IL
Denise Smith (Poster): Smith, D.C., Barton, A.J, Hernandez, T.L, Willems, E.L, Reed, S.M, Staley, A.W., Centi, S., & Anderson, J.L. (2022, May 22-26). The impact of a sudden shift to telehealth during the COVID19 pandemic on prenatal care and birth outcomes in a large nurse-midwifery service. [Poster presentation]. American College of Nurse-Midwives, Chicago, IL.
Elias A, Fornier M, Vidal G, Petricoin EF, Zolman K, Biller S, Alami V, Staley AW, McSpadden T, Borges VF, Gao D, Richer JF. Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer. Abstract ID: 1310755: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, Tx; American Association for Cancer Research; c2022
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D’Alessandro A, Zolman KL, Bokhoven A van, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin III EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. npj Breast Cancer [Internet]. 2023 May 20;9(1). Available from: http://dx.doi.org/10.1038/s41523-023-00544-z
Rusthoven CG, Staley AW, Gao D, Yomo S, Bernhardt D, Wandrey N, El Shafie R, Kraemer A, Padilla O, Chiang V, Faramand AM, Palmer JD, Zacharia BE, Wegner RE, Hattangadi-Gluth JA, Levy A, Bernstein K, Mathieu D, Cagney DN, Chan MD, Grills IS, Braunstein S, Lee CC, Sheehan JP, Kluwe C, Patel S, Halasz LM, Andratschke N, Deibert CP, Verma V, Trifiletti DM, Cifarelli CP, Debus J, Combs SE, Sato Y, Higuchi Y, Aoyagi K, Brown PD, Alami V, Niranjan A, Lunsford LD, Kondziolka D, Camidge DR, Kavanagh BD, Robin TP, Serizawa T, Yamamoto M. Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE). JNCI: Journal of the National Cancer Institute [Internet]. 2023 May 4;115(8):926–936. Available from: http://dx.doi.org/10.1093/jnci/djad073
Han DS, Walker JP, Nicklawsky A, Boxley P, Halstead NV, Tonzi M, Hecht SL, Staley A, Eguchi M, Cockburn MG, Roach JP, Saltzman AF, Cost NG. Pediatric Small Renal Masses: Can Tumor Size Predict Histology and the Potential for Nephron-sparing Surgery? Journal of Urology [Internet]. 2023 Mar;209(3):582–590. Available from: http://dx.doi.org/10.1097/JU.0000000000003092
Callahan R, Onyiah J, Bhagavatula G, Schaefer R, Staley A, Murphy E, Zhou L, Orlicky D, Atif S, Cartwright I, Hall C, Colgan S. Epithelial heme oxygenase-1 promotes colitis associated tumorigenesis through regulation of tumor epithelial differentiation and survival. Physiology [Internet]. 2023 May;38(S1). Available from: http://dx.doi.org/10.1152/physiol.2023.38.S1.5796045
Elias AD, Staley A, Fornier M, Vidal GA, Sams S, Spoelstra N, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle J, Petricoin E, Zolman K, Biller S, Alami V, McSpadden T, Borges V, Crump LS, Gao D, Richer JK. Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer. Cancer Research [Internet]. 2023 Apr 14;83(8_Supplement):CT144–CT144. Available from: http://dx.doi.org/10.1158/1538-7445.AM2023-CT144
Smith D, Thumm EB, Kissler K, Centi S, Anderson J, Reed S, Staley A, Hernandez T, Barton A. Sudden Shift to Telehealth in COVID-19: A Retrospective Cohort Study of Disparities in Use of Telehealth for Prenatal Care in a Large Midwifery Service. Journal of Midwifery and Women's Health [Internet]. Forthcoming 2023.
Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Goodspeed A, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle JD, Petricoin EF, Zolman KL, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER /Her2- breast cancer. NPJ Breast Cancer. 2024 Oct 6;10(1):88. PubMed PMID: 39368973
Winzent-Oonk S, Staley A, Alami V, Bradley J, Harvey S, Pounds A, Kuldanek S, Pacenta H, Winters AC, McKinney C. Risk of transfusion-related iron overload varies based on oncologic diagnosis and associated treatment: Retrospective analysis from a single pediatric cancer center. Pediatr Blood Cancer. 2024 Aug;72(1):e31254. PubMed PMID: 39118250
Tsui DCC, Holt DE, Patil T, Staley A, Gao D, Kavanagh BD, Schenk EL, Rusthoven CG, Camidge DR. The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer. Adv Radiat Oncol. 2024 Jul;9(7):101516. PubMed PMID: 38868503
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davies KD, Nijmeh H, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC. JTO Clin Res Rep. 2024 Feb;5(2):100637. PubMed PMID: 38361741
Smith DC, Thumm EB, Anderson J, Kissler K, Reed SM, Centi SM, Staley AW, Hernandez TL, Barton AJ. Sudden Shift to Telehealth in COVID-19: A Retrospective Cohort Study of Disparities in Use of Telehealth for Prenatal Care in a Large Midwifery Service. J Midwifery Womens Health. 2024 Jul-Aug;69(4):522-530. PubMed PMID: 38111228
Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle J, Petricoin E, Zolman K, McSpadden T, Rickert C, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamide. Poster session presented at: Proceedings of the 2024 San Antonio Breast Cancer Symposium; 2024 Dec 10-12; San Antonio, TX.
Nie Y, Staley A, Hinz T, Merrick D, Yang M, Schenk EL, Bunn PA, Camidge DR, Heasley L, Patil T. High PD-L1 expression among patients with ALK rearranged nonsmall cell lung cancer and response to first line ALK tyrosine kinase inhibitors. Journal of Clinical Oncology [Internet]. 2024 Jun 1;42(16_suppl):8626–8626. Available from: http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.8626
DeMarsh SJ, Ackley ER, Staley A, Dorris KM. QOL-53. EXPLORING HEADACHES IN PEDIATRIC NEURO-ONCOLOGY PATIENTS: A SINGLE INSTITUTION RETROSPECTIVE CHART REVIEW. Neuro-Oncology [Internet]. 2024 Jun 18;26(Supplement_4):0–0. Available from: http://dx.doi.org/10.1093/neuonc/noae064.641